NASDAQ · HINDHealthcarePharmaceuticals

Vyome Holdings financials

$2.02−0.49%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Revenue$27.0K$31.6K$36.6K$34.6K
Gross profit$11.7K$16.6K$22.1K$18.1K
Gross margin43.2%52.7%60.4%52.1%
Operating income-$862.6K-$1.1M-$1.4M-$8.6M
Net income-$685.6K-$1.0M-$1.5M-$8.4M
Net margin−2543.3%−3244.5%−4013.2%−24356.2%
Diluted EPS$-0.10$-0.15$-0.25$-3.06
EBITDA-$860.0K-$1.1M-$1.4M-$8.6M
Operating cash flow-$903.7K-$1.4M-$1.5M$4.3M
Free cash flow-$903.7K-$1.4M-$1.5M$4.3M
Diluted shares7.0M6.7M5.9M2.8M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30
Cash & equivalents$7.9M$8.8M$5.0M$5.7M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00
Total assets$9.2M$10.2M$6.5M$7.0M
Total liabilities$1.9M$2.1M$2.7M$3.1M
Shareholders' equity$7.3M$8.0M$3.8M$3.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology